Register for our free email digests:
Fovea Pharmaceuticals SA
Division of Sanofi
www.fovea-pharma.com
Latest From Fovea Pharmaceuticals SA
Finance Watch: Two More US Biopharma IPOs And Two New European VC Funds
Two biopharma IPOs in the US continue streak of (mostly) positive returns; two new European VC funds launch as Irish antibiotic developer raises $65m; and Halozyme, Ziopharm price offerings.
With Precedents In Place, GenSight Eyes Gene Therapies For Orphan Disorders
The Paris-based start-up has raised €32 million from venture investors to address two orphan eye disorders, taking advantage of new research and manufacturing techniques in gene therapy.
Financings of the Fortnight Comes Bearing Gifts
Plus recent news on Amarin, Moderna Therapeutics, ArmaGen and Flexion
British Biotechs Urge U.K. Government To Import French Private Investment Vehicle
British biotech companies want the U.K. government to adopt a French method of funneling funds into the cash-strapped sector from private individuals in return for favorable rates of investment tax, on grounds that a version of France’s long-running Fonds Commun de Placement dans l'Innovation is needed for small-to-medium-sized biopharma companies in Britain to tap successfully into long-term seed capital.
Company Information
- Industry
-
Biotechnology
- Large Molecule
- Pharmaceuticals
- Therapeutic Areas
- Ophthalmic
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
France
-
France
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Sanofi
- Senior Management
-
Bernard Gilly, PhD, Chmn. & CEO
Ulrich Adom, CFO
Soraya Bekkali, MD, CMO - Contact Info
-
Fovea Pharmaceuticals SA
Phone: (33) 44 16 42 42
Institut de la Vision
17 rue Moreau
Paris, 75012
France
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice